Botulinum toxin type A is under clinical development by Microgen and currently in Phase III for Spasmodic Torticollis (Cervical Dystonia). According to GlobalData, Phase III drugs for Spasmodic Torticollis (Cervical Dystonia) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Botulinum toxin type A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Botulinum toxin type A overview

Botulinum toxin A (Relatox) is a neuromuscular blocking agent which is produced from fermentation of hall strain clostridium botulinum type A. It is formulated as powder for solution for intramuscular route of administration. Relatox is indicated for the treatment of blepharospasm and correction of hyperkinetic facial wrinkles (expression lines) in adults.

Botulinum toxin A (Relatox) is also under development for the treatment of  migraine and spasmodic torticollis (cervical dystonia).

Botulinum toxin A (Relatox) was also under development for the treatment of  overactive bladder, neurogenic bladder dysfunction and upper limb muscle spasticity.

Microgen overview

Microgen is a manufacturer of immunobiological products and engaged in production of vaccines for the treatment of infectious diseases. Microgen is headquartered in Moscow, Russia.

For a complete picture of Botulinum toxin type A’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.